Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.
Fact checked by Nick Blackmer The Food and Drug Administration (FDA) on Thursday approved Journavx (suzetrigine), a new non-opioid painkiller that promises to be nonaddictive. Journavx is approved to ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.